Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew D Galsky

Showing results (11-20 of 389) with videos related to

Pageof 39
Sort By:
The Journal of Urology|March 20, 2012
Editorial commentMatthew D Galsky
European Urology|August 20, 2013
Metastatic renal cancer: better never than lateMatthew D Galsky
Journal of Geriatric Oncology|December 9, 2014
How I treat bladder cancer in elderly patientsMatthew D Galsky
Expert Opinion on Drug Safety|April 13, 2016
Adverse event reporting in oncology clinical trials - lost in translation?Shanthi Sivendran, Matthew D Galsky
Nature Reviews. Urology|January 21, 2015
Kidney cancer: Systemic therapy--differentiating the achievable from the achievedReza Mehrazin, Matthew D Galsky
Lancet (London, England)|December 20, 2020
PD-1 inhibitors for urothelial cancer: combination or sequential therapy? - Authors' replyMatthew D Galsky, Enrique Grande
European Urology|March 18, 2014
Targeting vascular endothelial growth factor receptor signaling in renal cancer: the sooner the better?Amanda Leiter, Matthew D Galsky
Future Oncology (London, England)|March 1, 2016
Systemic therapy for metastatic bladder cancer in 2016 and beyondAna Collazo-Lorduy, Matthew D Galsky
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2005
Bladder cancer "adjuvant-lite": tastes great (works as well) and less filling (less toxic)?Matthew D Galsky, Howard I Scher
Urologic Oncology|November 13, 2016
Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkersRandy F Sweis, Matthew D Galsky
Pageof 39

Showing results (11-20 of 389) with videos related to

Sort By:
Pageof 39
The Journal of Urology|March 20, 2012
Editorial commentMatthew D Galsky
European Urology|August 20, 2013
Metastatic renal cancer: better never than lateMatthew D Galsky
Journal of Geriatric Oncology|December 9, 2014
How I treat bladder cancer in elderly patientsMatthew D Galsky
Expert Opinion on Drug Safety|April 13, 2016
Adverse event reporting in oncology clinical trials - lost in translation?Shanthi Sivendran, Matthew D Galsky
Nature Reviews. Urology|January 21, 2015
Kidney cancer: Systemic therapy--differentiating the achievable from the achievedReza Mehrazin, Matthew D Galsky
Lancet (London, England)|December 20, 2020
PD-1 inhibitors for urothelial cancer: combination or sequential therapy? - Authors' replyMatthew D Galsky, Enrique Grande
European Urology|March 18, 2014
Targeting vascular endothelial growth factor receptor signaling in renal cancer: the sooner the better?Amanda Leiter, Matthew D Galsky
Future Oncology (London, England)|March 1, 2016
Systemic therapy for metastatic bladder cancer in 2016 and beyondAna Collazo-Lorduy, Matthew D Galsky
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2005
Bladder cancer "adjuvant-lite": tastes great (works as well) and less filling (less toxic)?Matthew D Galsky, Howard I Scher
Urologic Oncology|November 13, 2016
Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkersRandy F Sweis, Matthew D Galsky
Pageof 39